OXFORD NANOPORE TECHNOLOGIES

Oxford Nanopore wins UK injunction against MGI Tech, safeguarding its nanopore sequencing patents and strengthening its market leadership.

Oxford Nanopore Technologies’ shares dipped amid a wider FTSE 250 tech sell‑off, yet the biotech firm remains a leading force in DNA sequencing and molecular diagnostics.

Oxford Nanopore’s 60% monthly rally shows its new licensing strategy and sharp earnings turnaround, turning a tarnished reputation into a top FTSE 350 performer.

Oxford Nanopore Technologies faces market volatility amid U.S. Iran sanctions, balancing R&D, capital allocation, and geopolitical risks to sustain growth.

Oxford Nanopore’s Q1 earnings show narrowing losses, rising revenue and improved margins, while CEO incentives and FY27/FY28 guidance boost investor confidence.

Oxford Nanopore narrows 2026 losses, boosts margins and pledges FY27‑28 profitability, positioning itself as a financially disciplined biotech leader.

Oxford Nanopore Technologies: how its cutting‑edge DNA sequencing, diagnostics and drug‑development tools are reshaping healthcare and boosting market value.

Oxford Nanopore Technologies shares rise after directors exercise share‑incentive plan, reflecting confidence in its breakthrough DNA‑sequencing tech.

Oxford Nanopore misses first‑half revenue target as Chinese sales slump, yet keeps full‑year guidance steady, underscoring its resilience in molecular detection tech.